The introduction of new drugs into anaesthetic practice: a perspective in pharmaceutical development and regulation

Canadian Journal of Anaesthesia

Volumn 42, Issue 6, 1995, Pages 516-522

  Gilron, Ian ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Anaesthetics; Clinical pharmacology; Drug industry; Drug regulation

Indexed keywords

ANESTHETIC AGENT; NEW DRUG;

ANESTHESIA; DRUG APPROVAL; DRUG INDUSTRY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HISTORY OF MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

ANESTHETICS; DRUG AND NARCOTIC CONTROL; DRUG INDUSTRY; HUMAN;

EID: 0029073821     PISSN: 0832610X     EISSN: 14968975     Source Type: Journal    
DOI: 10.1007/BF03011691     Document Type: Article

References (53)

1. Anonymous. The testing of new drugs (Editorial). Br J Anaesth 1970; 42: 911.
2. Anaesthesia and clinical pharmacology: related disciplines
3. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development
4. The role of pharmacoepidemiology research in postmarketing surveillance and anesthesia practice/critical care medicine
5. Aspirin, the miracle drug: spinally, too?
6. The regulation of investigational drugs
7. The safety of new drugs (Editorial)
8. The practice of anesthesiology and the package insert: decision-making regarding drug use in anesthesiology (Editorial)
9. The pharmaceutical drug development process: an overview
10. Muscle relaxants
11. The development of alfentanil
12. Basic and clinical evaluation of new drugs
13. [3H]-sufentanil, a superior ligand for μ-opiate receptors: binding properties and regional distribution in rat brain and spinal cord
14. Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure
15. Phase IV study of propofol: validation of the data set
16. The Canadian drug regulatory process
17. Drug regulation — the Canadian approach
18. Regulation of anesthesia devices in the United States
19. Anaesthesia equipment safety in Canada: the role of government regulation
20. The Emergency Drug Release Program: regulatory aspects of new drug access in Canada
21. Succinylcholine (Editorial)
22. Intractable cardiac arrrest in children given succinylcholine (Letter)
23. Succinylcholine (Letter)
24. Succinylcholine: a premature death knell? (Editorial)
25. Revised label regarding use of succinylcholine in children and adolescents: II (Letter)
26. Unlabeled uses of approved drugs
27. The use of Food and Drug Administrationapproved medications for unlabelled (off-label) uses
28. Intravenous regional sympathetic block with guanethidine
29. New FDA intiatives
30. Paediatric labelling requirements: implications for pharmacokinetic studies
31. Addressing the pharmaceutical industry’s influence on professional behaviour (Editorial)
32. Impact of pharmaceutical company representatives on internal medicine residency programs
33. Ethical relationships between drug companies and the medical profession
34. The relationship between physicians in training and pharmaceutical companies (Editorial)
35. Doctors and detailers: therapeutic education or pharmaceutical promotion?
36. Doctors and the drug makers
37. Is it really free? (Letter)
38. Relationships with industry are OK if you follow the rules (Letter)
39. The publication of commercially sponsored supplements (Editorial)
40. Truth in advertising: the journal’s responsibility (Letter)
41. Unresolved issues relating to peer review, industry support of research, and conflict of interest. (Editorial)
42. Toxicity of compound A in rats: effect of a 3-hour administration
43. Toxicity of compound A in rats: effect of increasing duration of administration
44. The 31st Rovenstine lecture. The changing horizons in anesthesiology
45. The future of anesthesiology